Integrating anti-EGFR therapies in metastatic colorectal cancer. - Wikidata - awgldk - TriplyDB

Integrating anti-EGFR therapies in metastatic colorectal cancer.

Integrating anti-EGFR therapies in metastatic colorectal cancer.

http://www.wikidata.org/entity/Q43090496

about

Mechanisms underlying skin disorders induced by EGFR inhibitors The biological complexity of colorectal cancer: insights into biomarkers for early detection and personalized care Combination of gefitinib and DNA methylation inhibitor decitabine exerts synergistic anti-cancer activity in colon cancer cells Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways Primary and acquired resistance to biologic therapies in gastrointestinal cancers.Personalizing medicine for metastatic colorectal cancer: current developments.Colorectal carcinogenesis--update and perspectives.Multipoint Kras oncogene mutations potentially indicate mucinous carcinoma on the entire spectrum of mucinous ovarian neoplasms.Targeted therapies in colorectal cancer: the dos, don'ts, and future directions Meta-analysis of the mutational status of circulation tumor cells and paired primary tumor tissues from colorectal cancer patients.EGFR in Tumor-Associated Myeloid Cells Promotes Development of Colorectal Cancer in Mice and Associates With Outcomes of Patients.Genotypic and phenotypic signatures to predict immune checkpoint blockade therapy response in patients with colorectal cancer.ADAM17 is required for EGF-R-induced intestinal tumors via IL-6 trans-signaling.

P2860

Q26745689-0D863B5B-FE26-488A-BD43-57A67CFED031 Q28066460-A23A5CCC-CE5D-4594-B872-1E2A9B6A1229 Q28539177-33450CC4-C44E-4816-8988-4E3BE7C4DBA0 Q33737298-F88C4DAE-3DBE-43F8-90B0-7B3683F3EA12 Q33895573-5500BAB4-CE47-4FBB-9486-B4C2E32BC5F1 Q34036665-B66D598A-B1B1-4E4F-96CB-EF17AB3C9F3E Q34667352-7D1A9118-14F8-491A-B338-F0F1BEA20D33 Q37696086-1B3ABD65-A83C-40F3-80D3-2778A97178A6 Q39357003-FB8DB8D4-AAEF-44C0-84D7-F0604D5EF7EE Q43182172-F4049377-8925-47C2-A755-16046302B8A4 Q49861198-52D239C2-CD2F-4898-91E3-AB5188830ABE Q52666692-2D1E5155-BB87-48ED-A07F-251AA411DC38 Q52689175-C2238A23-6A8C-4ADF-A9F4-A57274751D7F

P2860

Integrating anti-EGFR therapies in metastatic colorectal cancer.

http://www.wikidata.org/entity/Q43090496

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Integrating anti-EGFR therapies in metastatic colorectal cancer.

@en

Integrating anti-EGFR therapies in metastatic colorectal cancer.

@nl

type

label

Integrating anti-EGFR therapies in metastatic colorectal cancer.

@en

Integrating anti-EGFR therapies in metastatic colorectal cancer.

@nl

prefLabel

Integrating anti-EGFR therapies in metastatic colorectal cancer.

@en

Integrating anti-EGFR therapies in metastatic colorectal cancer.

@nl

P1433

Q43090496-12D43FDC-4348-47B3-941D-1BF768635738

P1476

Q43090496-3FD49B3A-D3FE-4AE4-A51F-CDCC195D1456

P2093

Q43090496-0930ED2D-7C11-4265-9C8A-FD8E2533E90D

P2860

Q43090496-04D3CD52-5AD5-4D61-BB4A-61A71DA11E42

Q43090496-06BCB93B-BFDC-4DC2-9058-076B3EE4AF56

Q43090496-094F41FA-D889-48B4-B502-9687A26006E1

Q43090496-105B8BFE-ECC0-4A6A-84DA-3922015539D1

Q43090496-1346960F-EFA4-49C5-95F9-218A775EA663

Q43090496-16D579DD-50FE-4FE8-BB7B-5713AEBDBAFF

Q43090496-1B366DDB-257F-4CAF-A4BF-28AD64D312E6

Q43090496-1F6A65B3-B647-456D-B0D8-E661233E24D5

Q43090496-21C22D62-ABD7-4990-A48E-2EE7A4E526FB

Q43090496-2D18EC27-741D-4B13-8CFE-38AE912260DB

P304

Q43090496-B53D4E19-47F2-4BC1-BE69-BA654307B8F9

P31

Q43090496-C2FF02A4-FA82-4251-A5B0-A9D6E8C5FBFB

P356

Q43090496-741FF738-F29C-40A8-AE71-63EC5361E04A

P433

Q43090496-E5748B96-5B55-4745-98CB-61C7AC4F50D2

P478

Q43090496-85AFC178-80CF-4DF4-9E0C-441A4EA3797B

P50

Q43090496-2665C480-45A5-4652-ACE2-C85B847C3155

Q43090496-C213C3E9-F62B-45F5-9576-01D8DCF374BB

P577

Q43090496-8677223C-4509-4FC8-9E13-9DCE6CFEDAFC

P698

Q43090496-37EAAE2D-843C-43FE-84AF-F7DD06001B42

P921

Q43090496-1FF35B28-62E1-4DB0-B8D3-2BB43D7DE254

P932

Q43090496-F31135DE-6185-4C12-8972-B98ABD55FB82

P356

J.ISSN.2078-6891.2013.028

P1433

Journal of gastrointestinal oncology

P1476

Integrating anti-EGFR therapies in metastatic colorectal cancer.

@en

P2093

Tanios Bekaii-Saab

http://www.w3.org/2001/XMLSchema#string

P2860

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

EGFR gene copy number as a prognostic marker in colorectal cancer patients treated with cetuximab or panitumumab: a systematic review and meta analysis

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Cetuximab for the treatment of colorectal cancer.

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

P304

285-298

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3978/J.ISSN.2078-6891.2013.028

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Tanios Bekaii-Saab

Sigurdis Haraldsdottir

P577

2013-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23997940

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

3712294

http://www.w3.org/2001/XMLSchema#string